Compare GRC & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRC | KLRA |
|---|---|---|
| Founded | 1933 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1994 | 2026 |
| Metric | GRC | KLRA |
|---|---|---|
| Price | $67.18 | $11.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $84.33 | $43.00 |
| AVG Volume (30 Days) | 120.5K | ★ 780.6K |
| Earning Date | 10-23-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 32.03 | N/A |
| EPS | ★ 2.27 | N/A |
| Revenue | ★ $682,389,000.00 | N/A |
| Revenue This Year | $7.38 | N/A |
| Revenue Next Year | $5.65 | N/A |
| P/E Ratio | $30.22 | ★ N/A |
| Revenue Growth | ★ 3.44 | N/A |
| 52 Week Low | $43.68 | $9.76 |
| 52 Week High | $92.78 | $23.82 |
| Indicator | GRC | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.20 | 40.01 |
| Support Level | $65.04 | $9.76 |
| Resistance Level | $78.46 | $11.81 |
| Average True Range (ATR) | 2.23 | 1.01 |
| MACD | -0.29 | -0.18 |
| Stochastic Oscillator | 10.23 | 5.26 |
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of its revenue from the United States.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.